Extended Data Fig. 7: Anti-SARS-CoV-2 RBD monoclonal antibodies.
From: Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
a-c, Graphs show anti-SARS-CoV-2 neutralizing activity of monoclonal antibodies measured by a SARS-CoV-2 pseudotype virus neutralization assay using wild-type (Wuhan Hu-150) SARS-CoV-2 pseudovirus3,8. Half-maximal inhibitory concentration (IC50) values for antibodies from a, all clones and e, singlets isolated from COVID-19 convalescent individuals 1.33 and 6.27 months after infection or from vaccinated individuals after prime, and 1.3- or 5-months after 2 doses of vaccine. Each dot represents one antibody, where 451 total antibodies were tested including the 430 reported herein (Supplementary Table 5), and 21 previously reported antibodies13. Antibodies isolated from samples without a prime value are shown in black. Pie charts illustrate the fraction of non-neutralizing (IC50 > 1000 ng/ml) antibodies (grey slices), inner circle shows the number of antibodies tested per group. Horizontal bars and red numbers indicate geometric mean values. Statistical significance was determined by two-tailed Kruskal Wallis test with subsequent Dunn’s multiple comparisons, and for ring plots by two-tailed Fisher’s exact test with subsequent Bonferroni-correction. All experiments were performed at least twice.
